Cisplatin Dosing and Administration Guidelines
Introduction to Cisplatin Regimens
- The American Society of Clinical Oncology (ASCO) recommends cisplatin 100 mg/m² every 3 weeks for 3 cycles as a standard regimen for definitive concurrent chemoradiotherapy in head and neck squamous cell carcinoma, representing the highest-quality evidence-based standard 1, 2
- The ASCO/CSCO nasopharyngeal carcinoma guideline found no significant survival differences between weekly (40 mg/m²) and triweekly (100 mg/m²) schedules, with the weekly regimen showing improved quality of life 1
Dosing by Indication
- For head and neck cancer, a cumulative cisplatin dose of ≥200 mg/m² is critical for efficacy in concurrent chemoradiotherapy, with post-hoc analyses demonstrating that patients receiving <200 mg/m² cumulative dose have significantly worse overall survival 1, 2
- The ASCO guideline recommends cisplatin 50 mg/m² on days 1 and 8 every 4 weeks for 4 cycles combined with vinorelbine 25 mg/m² weekly for 16 weeks for non-small cell lung cancer in the adjuvant setting 4, 5, 6
- For anal squamous cell carcinoma, cisplatin 60 mg/m² on days 1 and 29 with maximum surface area of 2.0 m² (maximum single dose 120 mg) combined with 5-fluorouracil is recommended 7
Administration and Safety
- The National Comprehensive Cancer Network (NCCN) guidelines require mandatory pretreatment hydration with 1-2 liters of fluid infused for 8-12 hours prior to dosing, and the drug should be diluted in 2 liters of 5% Dextrose in 1/2 or 1/3 normal saline containing 37.5 g of mannitol and infused over 6-8 hours 3
- Repeat courses should not be given until serum creatinine is <1.5 mg/100 mL, BUN is <25 mg/100 mL, platelets ≥100,000/mm³, WBC ≥4,000/mm³, and audiometric analysis confirms auditory acuity within normal limits 3
- Compliance with planned dosing is frequently suboptimal, with the median administered dose of cisplatin being only 84% of the maximum intended in the JBR.10 trial 4, 5